Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

Russell J. Schilder,Harsh Pathak,Anna Lokshin,Robert W. Holloway,Ronald D. Alvarez,Carol Aghajanian,Hua Min,Karthik Devarajan,Eric A. Ross,Charles W. Drescher,Andrew K. Godwin

Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash

2009

Russell J. Schilder
Harsh Pathak
Anna Lokshin
Robert W. Holloway
Ronald D. Alvarez
Carol Aghajanian
Hua Min
Karthik Devarajan
Eric A. Ross
Charles W. Drescher
Andrew K. Godwin

Objectives Determine if cetuximab dose escalation to induce grade 2 rash correlates with anti-tumor activity and if sera-based markers could predict likelihood of response.

Keywords:

Gynecology
Ovarian cancer
Clinical trial
Rash
Cetuximab
Oncology
Primary peritoneal carcinoma
Acneiform eruption
Peritoneal Neoplasm
Internal medicine
Medicine
Pathology
dose escalation
Immunology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations